BioNTech Soars 10.44% on Strategic Partnership, Earnings

BioNTech's stock surged by 10.44% in pre-market trading on June 2, 2025, marking a significant rise for the biotechnology company.

Morgan Stanley recently adjusted its target price for BioNTech, lowering it from $140.00 to $132.00 while maintaining an "overweight" rating for the company. This adjustment reflects the firm's ongoing evaluation of BioNTech's financial performance and market prospects.

BioNTech and Bristol Myers Squibb (BMS) have announced a strategic partnership for the joint development and manufacturing of their products. The collaboration will see both companies sharing costs and profits on a 50:50 basis, subject to certain exceptions. This partnership is expected to enhance BioNTech's operational efficiency and market reach.

In the first quarter of 2025, BioNTech reported a loss but maintained its financial guidance for the year. The company also welcomed Ramón Zapata-Gomez as its new Chief Financial Officer, a move aimed at strengthening its financial management and strategic planning.